Xencor’s (XNCR) “Buy” Rating Reiterated at Piper Jaffray Companies

Piper Jaffray Companies reaffirmed their buy rating on shares of Xencor, Inc. (NASDAQ:XNCR) in a research note issued to investors on Sunday. They currently have a $35.00 price objective on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the company. Zacks Investment Research downgraded Xencor from a hold rating to a sell rating in a research note on Friday, August 11th. Canaccord Genuity restated a buy rating and set a $36.00 price target on shares of Xencor in a research note on Tuesday, August 8th. ValuEngine downgraded Xencor from a hold rating to a sell rating in a research note on Monday, October 23rd. Finally, BidaskClub downgraded Xencor from a hold rating to a sell rating in a research note on Monday, August 14th. Three research analysts have rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. Xencor currently has a consensus rating of Hold and a consensus target price of $30.25.

Xencor (NASDAQ XNCR) opened at $20.29 on Friday. Xencor has a 52-week low of $18.55 and a 52-week high of $29.38.

COPYRIGHT VIOLATION WARNING: “Xencor’s (XNCR) “Buy” Rating Reiterated at Piper Jaffray Companies” was first published by Week Herald and is the sole property of of Week Herald. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://weekherald.com/2017/11/15/xencors-xncr-buy-rating-reiterated-at-piper-jaffray-companies.html.

In related news, major shareholder John S. Stafford III acquired 43,500 shares of the business’s stock in a transaction that occurred on Friday, August 18th. The stock was bought at an average cost of $19.93 per share, for a total transaction of $866,955.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder John S. Stafford III acquired 41,016 shares of the business’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were bought at an average price of $19.69 per share, with a total value of $807,605.04. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 405,933 shares of company stock valued at $8,087,759. Corporate insiders own 4.14% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Equitec Specialists LLC bought a new position in shares of Xencor during the 2nd quarter valued at approximately $116,000. Great West Life Assurance Co. Can grew its stake in shares of Xencor by 158.9% during the 3rd quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 4,005 shares during the period. SG Americas Securities LLC grew its stake in shares of Xencor by 62.6% during the 2nd quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock valued at $178,000 after acquiring an additional 3,252 shares during the period. Principal Financial Group Inc. bought a new position in shares of Xencor during the 3rd quarter valued at approximately $201,000. Finally, Legal & General Group Plc grew its stake in shares of Xencor by 4.5% during the 2nd quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 385 shares during the period. Institutional investors own 76.70% of the company’s stock.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply